- Home
- ECBK vs DMAC Comparison
ECBK vs DMAC Comparison
Compare ECBK & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- DMAC
- Stock Information
- Founded
- ECBK 1919
- DMAC 2000
- Country
- ECBK United States
- DMAC United States
- Employees
- ECBK N/A
- DMAC N/A
- Industry
- ECBK Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- DMAC Health Care
- Exchange
- ECBK Nasdaq
- DMAC Nasdaq
- Market Cap
- ECBK 151.0M
- DMAC 178.0M
- IPO Year
- ECBK N/A
- DMAC N/A
- Fundamental
- Price
- ECBK $16.20
- DMAC $3.63
- Analyst Decision
- ECBK
- DMAC Strong Buy
- Analyst Count
- ECBK 0
- DMAC 2
- Target Price
- ECBK N/A
- DMAC $8.00
- AVG Volume (30 Days)
- ECBK 67.4K
- DMAC 325.9K
- Earning Date
- ECBK 08-08-2025
- DMAC 08-06-2025
- Dividend Yield
- ECBK N/A
- DMAC N/A
- EPS Growth
- ECBK 17.87
- DMAC N/A
- EPS
- ECBK 0.57
- DMAC N/A
- Revenue
- ECBK $26,906,000.00
- DMAC N/A
- Revenue This Year
- ECBK N/A
- DMAC N/A
- Revenue Next Year
- ECBK N/A
- DMAC N/A
- P/E Ratio
- ECBK $28.23
- DMAC N/A
- Revenue Growth
- ECBK 5.99
- DMAC N/A
- 52 Week Low
- ECBK $12.50
- DMAC $2.98
- 52 Week High
- ECBK $16.99
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ECBK 59.34
- DMAC 44.55
- Support Level
- ECBK $15.81
- DMAC $3.48
- Resistance Level
- ECBK $16.45
- DMAC $3.88
- Average True Range (ATR)
- ECBK 0.40
- DMAC 0.26
- MACD
- ECBK 0.11
- DMAC 0.00
- Stochastic Oscillator
- ECBK 81.85
- DMAC 30.10
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.